B2B-Uro-oncology: GU Cancer Triad Meeting

This one-and-a-half-day event, featuring world renowned experts, will focus on the latest research in the top three urological cancers – bladder, kidney, and prostate.

Tremendous advancements have been made in diagnosis and treatment with the recent FDA approval of a targeted therapy for metastatic bladder cancer with FGFR3 or FGFR2 genetic alterations, two combination immunotherapy-targeted therapies as first-line treatment for advanced RCC, as well as advances in diagnostics and immunotherapy research for prostate cancer

Take advantage of this highly anticipated event and immerse yourself in the evolving landscape of urological cancer care.

Scientific Programme Committee:

• Peter Black (Canada)
• Peter Hammerer (Germany)
• Piilar Laguna (Turkey)
• Rafael Sanchez-Salas

Weitere Informationen finden Sie hier.